<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131533</url>
  </required_header>
  <id_info>
    <org_study_id>2010_134</org_study_id>
    <nct_id>NCT01131533</nct_id>
  </id_info>
  <brief_title>Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human</brief_title>
  <official_title>Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators investigate intraocular concentrations and pharmacokinetics of
      erythropoietin after a single intravitreal injection in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravitreal injections of erythropoietin for off-label use have been shown to be beneficial
      in eyes with diabetic macular edema.However, the pharmacokinetic profile of erythropoietin
      after intravitreal injection in humans has not yet been determined clearly. The purpose of
      this study was to determine the intraocular pharmacokinetics of erythropoietin after a single
      intravitreal injection in a prospective investigation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of erythropoietin in aqueous humor</measure>
    <time_frame>a few seconds</time_frame>
    <description>erythropoietin injections had been performed in our department following standard procedures. In selected cases,vitrectomy was performed one to two days after erythropoietin injection to treat diabetic macular edema.During surgery, aqueous humor samples were obtained via a corneal paracentesis anterior to the limbus at the beginning of the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of erythropoietin in vitreous</measure>
    <time_frame>few minutes</time_frame>
    <description>erythropoietin injections had been performed in our department following standard procedures. In selected cases,vitrectomy was performed one to two days after erythropoietin injection to treat diabetic macular edema.During surgery, vitreous samples were obtained via vitreous cutter at the beginning of the procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Erythropoietin</condition>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with chronic macular edema associated with diabetic retinopathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrectomy</intervention_name>
    <description>vitrectomy following intravitreal erythropoietin</description>
    <arm_group_label>Erythropoietin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetic macular edema that failed to respond to or recurred after the previous
             macular focal laser photocoagulation or intravitreal therapy, or both.

          -  visual acuity worse than 40/200 snellen bisual acuity

        Exclusion Criteria:

          -  Eyes with vitreomacular traction, active proliferative diabetic retinopathy,
             intraocular inflammation, uncontrolled intraocular pressure , cataract surgery within
             the past six months, or a prior history of vitreoretinal surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JiWon Lim</last_name>
    <phone>82-33-240-5176</phone>
    <email>jiwoneye@hallym.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hoapital</name>
      <address>
        <city>Chuncheon</city>
        <state>Kangwondo</state>
        <zip>200-704</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JiWon Lim</last_name>
      <phone>82-33-240-5176</phone>
      <email>jiwoneye@hallym.or.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Li W, Sinclair SH, Xu GT. Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):18-25. doi: 10.3928/15428877-20091230-03.</citation>
    <PMID>20128565</PMID>
  </results_reference>
  <results_reference>
    <citation>Lagr√®ze WA, Feltgen N, Bach M, Jehle T. Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol. 2009 Dec;93(12):1667-71. doi: 10.1136/bjo.2008.156794. Epub 2009 Aug 18.</citation>
    <PMID>19692373</PMID>
  </results_reference>
  <results_reference>
    <citation>Song BJ, Cai H, Tsai JC, Chang S, Forbes M, Del Priore LV. Intravitreal recombinant human erythropoietin: a safety study in rabbits. Curr Eye Res. 2008 Sep;33(9):750-60. doi: 10.1080/02713680802366602.</citation>
    <PMID>18798078</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang J, Wu Y, Jin Y, Ji F, Sinclair SH, Luo Y, Xu G, Lu L, Dai W, Yanoff M, Li W, Xu GT. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008 Feb;49(2):732-42. doi: 10.1167/iovs.07-0721.</citation>
    <PMID>18235022</PMID>
  </results_reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>September 14, 2010</last_update_submitted>
  <last_update_submitted_qc>September 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>hallym unuversity medical center</name_title>
    <organization>department of ophthalmology</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

